# A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

> **NCT02038777** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** PF-04449913
- **DRUG:** PF-04449913
- **DRUG:** Low dose ARA-C (LDAC)
- **DRUG:** PF-04449913
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** PF-04449913
- **DRUG:** Azacitidine
- **DRUG:** PF-04449913
- **DRUG:** LDAC

## Key facts

- **NCT ID:** NCT02038777
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-25
- **Primary completion:** 2021-02-12
- **Final completion:** 2023-12-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038777, "A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02038777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*